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Summary.-Chinese hamster V79 cells cultured in vitro were used to investigate the
cytotoxicity of various anti-cancer drugs subsequent to a prolonged treatment of
the cells with Misonidazole (MISO). The sensitivity of the cells to Bleomycin (BLM),
Melphalan or cis-Platinum (cis-DDP) was significantly increased by prior incubation
with MISO under hypoxic conditions. When cysteamine, a radical scavenger, was
present during the pretreatment with MISO, this enhancement of cytotoxicity was
greatly reduced.
These experiments, suggest that MISO by virtue of its selective toxicity towards
hypoxic cells and its enhancement of cell killing by anti-neoplastic drugs, can play an
important role in cancer chemotherapy.
THE POSSIBILITY that hypoxic cells in
solid tumours may limit successful local
control of these tumours by X-rays has
been recognized by radiation oncologists
for more than a quarter of a century
(Thomlinson & Gray, 1955). The realiza-
tion that hypoxia may also be a factor of
importance in chemotherapy is much
more recent (Roizin-Towle & Hall, 1978).
Over the years, a substantial effort has
been devoted to developing methods to
overcome the problem of hypoxic cells in
radiotherapy, the most recent of which
involves the use of heterocyclic nitro
compounds that mimic 02 and interact
with radiation to increase specifically the
sensitivity of hypoxic cells, while not
affecting the response of normal aerated
cells (Adams & Cooke, 1969). A number of
compounds have been identified and
studied in experimental systems, and one
ofthem, misonidazole (MISO), has already
been introduced into clinical trials. In
addition to preferentially sensitizing hy-
poxic cells, MISO is also preferentially
cytotoxic to cells deficient in 2. This has
been reported for single cells in vitro (Hall
& Roizin-Towle, 1975; Mohindra & Rauth,
1976; Moore et al., 1976; Stratford &
Adams, 1977), for cells in multicellular
spheroids (Sutherland et al., 1976) and in
solid tumours in experimental animals
(Denekamp & Harris, 1976; Brown, 1975;
Fowler et al., 1976). This cytotoxicity also
proved to be strongly dependent on
temperature (Stratford & Adams, 1977;
Hall et al., 1977). Hypoxia may limit the
efficiency of chemotherapy in several ways
(Roizin-Towle & Hall, 1978; Lin et al.,
1976). In some cases, drug availability
may be a severe limitation, since cells
deficient in 02 are of necessity located
some distance from a capillary. If 02
does not reach them, some drugs may not
either. A second factor is that cells at low
02 tension are likely to be slow-cycling,
or out of cycle altogether, making them
relatively resistant particularly to drugs
that are cycle-specific. Based on this
reasoning, it was suggested that a com-
pound such as MISO would be a logical
addition to a chemotherapy cocktail toL. A. ROIZIN-TOWLE AND E. J. HALL
effectively kill the hypoxic cells that are
resistant to conventional chemotherapy
(Roizin-Towle & Hall, 1978).
This initial suggestion that the toxicity
to hypoxic cells of electron-affinic agents
might be valuable in combination with
antineoplastic agents was based on the
premise that they would act in a way that
was complementary but independent, i.e.,
that the hypoxia-mediated drugs would
kill the hypoxic cells spared by the con-
ventional chemotherapy agents. Suther-
land et al. (1979) showed that when MISO
wasusedtopretreatmulticellularspheroids
before the addition of Adriamycin, the
number of clonogenic cells per spheroid
was much less than with either agent
alone, though the results are consistent
with independent action of the two drugs.
There is now good evidence, however,
of a direct interaction between electron-
affinic compounds and other antineoplastic
agents (Stratford et al., 1980). Rose et al.
(1980) investigated the response of the
Lewis lung tumour in mice to. the com-
bined effects of MISO with antineoplastic
agents, including Melphalan, cyclophos-
phamide, 5-fluorouracil and cis-platinum.
The present investigation extends the
range of chemotherapy agents known to
interact with MISO to include Bleomycin,
and in particular addresses itself to the
question of the mechanism of the inter-
action.
MATERIALS AND METHODS
Chinese hamster V79 cells were used for
these experiments, grown in GIBCO FIO
culture medium, supplemented with 10%
foetal calf serum and antibiotics.
Drug treatments were performed at 37 5°C,
with the cells maintained in suspension in
specially made glass vessels based on the
design of Chapman & Urtasun (1977). These
vessels include a magnetic stirrer to keep the
cells in suspension, inlet and outlet portals to
allow the suspension to be rendered aerated
or hypoxic by the use of a suitable gas mix-
ture, and a facility to allow cell samples to
be withdrawn with a small pipette without
significantly disturbing the 02 status of the
cell suspension.
On the day of an experiment, cells in expo-
nential growth were harvested by trypsiniza-
tion from several large Falcon culture flasks
(75 cM2) and prepared into a suspension
which was shared between the various treat-
ment vessels and diluted to a final concentra-
tion of 106 cells/ml after the addition of the
various drugs according to the plan of the
particular experiment.
In many experiments to be described, cells
were treated with MISO before exposure to
various antineoplastic agents. In such cases,
the cells were removed from suspension by
centrifugation, so that the MISO could be
diluted out before subsequent treatments
with chemotherapy agents.
During treatment with MISO or various
chemotherapy agents, cell samples were
withdrawn from the cell suspension at fre-
quent intervals, and various aliquots plated
into culture flasks containnig fresh growth
medium, to assay for colony formation. Care
was taken to ensure that the drug concentra-
tion introduced into the flasks used to assess
colony formation was not sufficient to affect
the plating efficiency.
All drug solutions were made up fresh the
day ofan experiment in FIO culture medium.
They were filter-sterilized and diluted with
culture medium to the desired final concentra-
tion. Bleomycin was generously donated
by Bristol Laboratories, Syracuse, New York.
Melphalan and cis-platinum (cis-DDP) were
supplied bytheDrug Synthesis and Chemistry
Branch of the National Cancer Institute.
Cysteamine was purchased from Sigma
Chemical Company of St Louis, Missouri.
At the conclusion of all drug treatments,
the cell samples were plated into sealed
Falcon flasks (25 cm2) and incubated for 8
days at 37 5°C, when they were fixed, stained
and the macroscopic colonies per flask were
counted.
RESULTS
The datapresented in Figs 1-7 represent
various sequences of drug combinations,
involving MISO, cysteamine and 3 anti-
neoplastic agents. Each experiment was
repeated several times, with the same
conclusions. However, in our experience
with some antineoplastic agents in vitro,
different drug batches vary so much that
it is not practical to pool data from experi-
ments performed over a period of time.
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Consequently each figure includes data
from one large self-contained experiment.
Each point plotted is the mean of 3-6
replicate flasks and the error bars represent
the standard error.
Fig. 1 shows the effect of pretreating
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FIG. 1.-The left-hand panel shows the frac-
tion of cells surviving the 3h pretreatment
under air orhypoxia, with orwithoutMISO.
The right-hand panel shows the fraction of
cells surviving treatment with BLM after
the various pretreatments.
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FIG. 2. The left-hand panel shows the
fraction of cells surviving the 3h pre-
treatment under hypoxia, with MISO,
BLM, or no added drug. The right-hand
panel shows the fraction of cells surviving
treatment with BLM orMISOafter various
pre-treatments.
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FIG. 3.-The left-hand panel shows the frac-
tion of cells surviving a 3h pretreatment
under hypoxia with or without 5mM MISO
and 5mM cysteamine. The right-hand panel
shows the fraction of cells surviving treat-
ment with BLM after the various pre-
treatments.
cells under aerated or hypoxic conditions
with or without 5mM MISO, before a
further exposure in air to 100 ,ug/ml of
Bleomycin for 0-3 h.
Fig. 2 shows the results of an experi-
ment designed to investigate the impor-
tance of the sequence of drug treatments.
Cells were pretreated with MISO, followed
by BLM, or vice versa; hypoxia was main-
tained throughout. It is evident that the
fraction of cells surviving the two treat-
ments is lower by two orders ofmagnitude
when MISO precedes BLM, than with the
reverse sequence.
The data in Fig. 3 show again that
hypoxic pretreatment with MISO greatly
enhances the subsequent cytotoxicity of
BLM, but that the enhancement can
be blocked to alarge extent bythe addition
of an equimolar concentration of cystea-
mine during the pre-incubation.
Fig. 4 shows data from 2 experiments in
which cells under aerated conditions
received 0-5h exposure to 100 ,ug/ml of
BLM, with or without simultaneous 5mM
cysteamine. The data indicate that cystea-
mine decreases the effectiveness ofBLM in
cell killing when present at the same time.
Fig. 5 shows the effect of treating cells
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under hypoxic conditions with or without
MISO, followed by an exposure in air to
0 5 ,g/ml of Melphalan. The data in this
figure show first, that pretreatment with
MISO enhances subsequent cell killing by
Melphalan, and second, that this enhance-
ment can be largely reversed if the pre-
lo-
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FIG. 4.-Data to show the cytoxicity of
BLM at 100 ,g/ml for various periods of
time under aerated conditions (solid
symbols) and the extent to which this
cytotoxicity can be blocked by the simul-
taneous administration of 5mM eysteamine
(open symbols).
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FIG. 5.-The left-hand panel shows the frac-
tion of cells surviving a 3h pretreatment
under hypoxia with or without MISO and/
or cysteamine. The right-hand panel shows
the fraction of cells surviving treatment
with Melphalan (0 5p g/ml) after the
various pretreatments.
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FIG. 6. The left-hand panel shows the frac-
tion of cells surviving a 3h hypoxic pre-
treatment with or without MISO and/or
eysteamine. Also shown is the 3 h survival
for cells exposed in air to 15,um cis-DDP.
The right-hand panel shows the fraction of
cells surviving various treatments of cis-
DDP at 15ItM after the various pretreat-
ments, or of cells surviving treatment with
MISO under hypoxia, after 151tM cis-DDP
in air.
treatment with MISO involves a simul-
taneous exposure to 5mM cvsteamine.
The data in Fig. 6 show the effect of
pretreating cells with MISO under hypoxic
conditions, with or without cysteamine,
and the subsequent response in air to
15,tM cis-DDP. The enhancement by
MISO of cis-DDP toxicity is shown,
and also that treating cells with cis-DDP
before MISO has no apparent enhancing
effect. The data also show that the
presence of cysteamine during the pre-
treatmentwithMISO reduces the enhance-
ment ofthe cis-DDP cytotoxicity.
DISCUSSION
The experiments described confirm pre-
vious reports in the literature that
pretreatment with MISO strikingly poten-
tiates the cytotoxicity of Melphalan and
cis-DDP (Stratford et al., 1980) while
adding the new information that BLM
killing is also greatly enhanced. The poten-
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tiation produced by pretreatment with
MISO occurs only if this pretreatment is
under hypoxia. The subsequent exposure
to the chemotherapeutic agent may be
under aerated or hypoxic conditions; this
has been showvn for BLM in the present
paper, but other unpublished data indi-
cates that it is true also for Melphalan and
cis-DDP.
The initial idea that MISO may have a
place in a chemotherapy cocktail, to
sterilize the hypoxic cells that are resistant
to killing by the more conventional anti-
neoplastic agents (Roizin-Towle & Hall,
1978) now gives way to the wider claim
that there is an interaction between the
two classes of agents, i.e. that MISO
potentiates a wide range of chemothera-
peutic agents.
The present experiments, designed to
reveal the mechanism of these effects,
demonstr-ate that the concomitant applica-
tion ofcysteamine during the pretreatment
with MISO inhibits the enhancement by
MISO of the subsequent cytotoxicity of
BLM, cis-DDP and Melphalan. Since
cysteamine is a free-radical scavenger,
free radicals are strongly implicated in
the mechanism of the enhancement of the
action of chemotherapeutic agents by
MISO (Hall & Biaglow, 1977). The inhibi-
tion by cysteamine of the cytotoxicity
of BLM (Fig. 4) is strong circumstantial
evidence that the action of this drug is
also mediated through free radicals, which
correlates with previous findings (Buettner
& Oberley, 1.979; Fukuoka et al., 1.980).
MISO has now been shown to have three
distinct properties:
First, it, preferentially sensitizes hypoxic
cells to killing by X-rays. The enhance-
ment of radiosensitivity is dose-modifying
if the radiation is delivered shortly after
the addition of MISO, but if cells are pre-
incubated under hypoxia for some hours
before irradiation, the radiosensitization
is increased, and MISO ceases to be dose-
modifying, in that the shoulder to the sur-
vival curve is reduced (Hall & Biaglow,
1977; Wfong et al., 1978).
Second, it is cytotoxic to mammalian
cells, though extended contact for several
hours is necessary for substantial cell
killing to become apparent. Again hypoxic
cells are affected differentially since 100-
fold concentrations are required for equal
cell killing in aerated cells.
Third, pre-incubation with MISO poten-
tiates or enhances the cytotoxicity pro-
duced by a subsequent exposure to a
number of chemotherapeutic agents, in-
cluding alkylating agents and antibiotics.
In experiments with cells cultured in vivo,
the pretreatment must be under hypoxia
for the maximum enhancement of cyto-
toxic effect, but in solid tumours in
laboratory animals, the degree ofpotentia-
tion is perhaps too much to be explained
as an effect on hypoxic cells only.
The mechanism for hypoxic-cell toxicity
by MISO is believed to be the metabolic
reduction of the nitro group to stable
intermediates, which then bind to cellular
macromolecules causing DNA damage
and interfere with electron transport
(Olive, 1980). While depletion of thiols
plays an important role in hypoxia-
mediated cytotoxicity by MISO, other
biochemical mechanisms must clearly play
a role as well (Kinnula & Hassinen, 1980).
These other effects were demonstrated at
the ultrastructural level, where treating
cells under hypoxia with MISO for 3 h
produced such severe damage to the
endoplasmic reticulum and mitochondria
that damage to glycolytic processes and
malfunctioning enzymic repair processes
seemed inescapable (Roizin-Towle et al.,
1977). It appears that many factors are
operating, and a complicated interplay
of biochemical reactions may occur during
hypoxia (Rudolf, 1980)-an area of re-
search that requires further investigation,
especially with regards to cancer-drug
metabolism, toxicity and interaction with
other agents.
At the mechanistic level, the question
is whether these diverse properties of
MISO are related. The straightforward
radiosensitizing properties are adequately
accounted for in terms of the electron
affinity ofMISO and in its ability to mimic
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02. The other properties, including the
changing radiosensitization with time, the
cytotoxicity of MISO and its ability to
potentiate the cytotoxicity of various
chemotherapeutic agents, all require pro-
longed incubation of cells with the drug
under hypoxic conditions. This in turn
involves the breakdown and metabolism
of the drug (Whitmore & Guylas, 1980).
It is possible, therefore, that a common
mechanism maybe involved.
In the report which first described the
increase of radiosensitization with storage
(Hall & Biaglow, 1977) it was postulated
that this was due to the depletion in the
cells of natural sulphydryl compounds,
particularly thiols. The substantial body of
new data, as well as the new phenomena
discovered since, appear to be compatible
with this hypothesis. In particular, the
potentiation of chemotherapy agents by
pretreatment with MISO is readily ex-
plainedin these terms. Prolonged exposure
to MISO under hypoxia is required to
deplete the cells of thiols, following which
the cells are very sensitive to killing by
chemotherapy agents-particularly those
that produce their cytotoxicity via free
radicals. The replacement of these thiols
by cysteamine, as shown in these data,
lends support to this idea. Free radicals
are also involved in the cytotoxicity of
BLM, which can be blocked by the addi-
tion of cysteamine, a radical scavenger.
On the other hand, the cytotoxicity of
BLM is greatly enhanced when cells are
pretreated with MISO.
This effect of MISO is likewise remem-
bered by cells when they are subsequently
treated with Melphalan or cis-DDP, show-
ing that it enhances the action of other
chemotherapeutic agents as well. Since
MISO shows little toxicity to aerated
cells, its use in combination with other
established cancer drugs would be bene-
ficial for two reasons. First, it would selec-
tively kill hypoxic cells and secondly, it
would subsequently reduce the systemic
dose of chemotherapeutic drugs needed
to produce a certain level of cell kill not
achievable on their own.
The investigation described here lends
strong support to the contention that
the hypoxia-mediated electron-affinic
compounds such as Misonidazole, devel-
oped initially as radiosensitizers, have a
place in chemotherapy. Their selectivity
for hypoxic cells, and their enhancement
of killing by chemotherapeutic agents,
show the importance for a calculated
exploitation ofdrug-delivery sequences.
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